BioMarin stock rating reiterated at Buy by Stifel on strong Q2 results

BioMarin Pharmaceutical Inc. (BMRN) reported robust second-quarter financial results, significantly exceeding analyst expectations with revenue of $825 million and EPS of $1.44, leading to a raised full-year EPS guidance. This strong performance, driven by 20% growth in Voxzogo and 15% in enzyme revenues, prompted multiple analysts including Stifel, UBS, Bernstein, and TD Cowen to reiterate Buy/Outperform ratings and raise price targets. Despite the positive financials and strong operational efficiency, investor focus remains on competition in the Achondroplasia market and the BMN333 pipeline, with Stifel suggesting the current stock price over-accounts for competitive risks while under-valuing growth opportunities.

Analysis

BioMarin Pharmaceutical (BMRN) delivered a robust second quarter, significantly outperforming market expectations and prompting a positive revision to its full-year earnings guidance. The company reported revenue of $825 million, an 8% beat over the $753 million consensus, and earnings per share of $1.44, a striking 73.5% surprise above the $0.83 forecast. This performance was underpinned by strong product sales, including a 20% year-over-year growth in Voxzogo and a 15% increase in enzyme revenues. The results reflect strong operational health, evidenced by a perfect Piotroski Score of 9, a gross margin of 81%, and a current ratio of 5.5. Despite these impressive fundamentals and a wave of positive analyst sentiment—including reiterated Buy ratings from Stifel, UBS, and TD Cowen with price targets ranging from $91 to $120—a key disconnect persists with investor sentiment. The market's focus remains narrowly fixed on future competition in the Achondroplasia market and the development of BMN333, the company's next-generation CNP candidate. Stifel's analysis suggests the current stock price has excessively discounted these competitive risks while failing to adequately price in growth drivers such as the potential expansion of Voxzogo's indications and other pipeline opportunities.

Key Decisions for Investors

• Given the significant Q2 earnings beat, raised EPS guidance, and strong analyst consensus, investors could view the current valuation as an attractive entry point, as the stock appears to be trading below its intrinsic value according to Stifel and InvestingPro.
• Monitor the upcoming medical meeting for the complete Phase 1 data release on BMN333, as this will be a critical catalyst to either validate or challenge the market's concerns regarding the company's competitive positioning in the CNP franchise.
• Consider that the market may be overly focused on competitive threats, potentially creating a mispricing opportunity by overlooking the upside from Voxzogo's indication expansion and the broader strength of the enzyme replacement therapy business.
• Investors should weigh the company's demonstrated operational discipline and strong financial health, including an 81% gross margin and a Piotroski Score of 9, against the forward-looking pipeline and competitive risks that are currently influencing investor positioning.